# Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement

> **NCT00403234** · PHASE2 · TERMINATED · sponsor: **Purdue Pharma LP** · enrollment: 10 (actual)

## Conditions studied

- Postoperative Pain

## Interventions

- **DRUG:** Buprenorphine transdermal patch
- **DRUG:** Buprenorphine transdermal patch
- **DRUG:** Buprenorphine transdermal patch
- **DRUG:** Placebo BTDS

## Key facts

- **NCT ID:** NCT00403234
- **Lead sponsor:** Purdue Pharma LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2007-04
- **Final completion:** 2007-08
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** due to administrative reasons not related to efficacy or safety.
- **Last updated:** 2012-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00403234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00403234, "Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00403234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*